Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

More aggressive treatment not necessary for men with a family history of prostate cancer

06.10.2011
Approximately 10-20 percent of prostate cancer patients have a family history of the disease. There are three major factors that are used to evaluate the extent and aggressiveness of prostate cancer, help make treatment decisions, and estimate prognosis: the Prostate Specific Antigen Level (PSA), Gleason score (GS) from the biopsy, and the digital rectal exam findings (DRE).

However, men with a family history of prostate cancer have often been feared to have a more aggressive form of the disease not otherwise represented by these three factors and therefore are sometimes urged to undergo more aggressive treatment.

Now, Mark Buyyounouski, M.D., M.S., a radiation oncologist at Fox Chase, reports that men with a family history of prostate cancer should expect equally good outcomes following radiotherapy for prostate cancer as patients without a family history. Buyyounouski will be introducing the new data at the 53rd annual meeting of the American Society of Radiation Oncology on Wednesday, October 5th.

PSA, GS, and DRE are well established risk factors for prostate cancer that are used everyday to help make decisions about what treatment option may be best for a patient with the disease. These factors appear in both the American Joint Cancer Commission (AJCC) and National Comprehensive Cancer Network (NCCN) model to stratify risk of recurrence and guide treatment. Yet, in some instances, physicians use a family history of prostate cancer to evaluate the degree of risk associated with the cancer and recommend more aggressive treatment.

In the study, Buyyounouski and his team of collaborators examined 1,711 men who received three-dimensional conformal (3DCRT) or intensity modulated radiotherapy (IMRT) between 1989 and 2007 at Fox Chase Cancer Center in Philadelphia. A positive family history was defined as any prostate cancer in one or more first-degree relatives. Twenty-eight percent of the patients had a positive family history for prostate cancer. The median follow-up from completion of treatment was 71 months.

"What we learned was that whether the men had a history of prostate cancer or not, all had equivalent PSA controls, freedom from metastasis, recurrence-free survival, and overall survival," says Buyyounouski. "Patients should feel comfortable knowing that when they receive radiotherapy having a history of prostate cancer in the family doesn't compromise the results. This is important because patients, especially those with a family history, might assume that radiotherapy might not work as well and opt for surgery when it may not be necessary."

Interestingly, Buyyounouski and his colleagues also learned that men with a family history of prostate cancer were more likely to be younger, have a lower PSA, and non-palpable disease.

"This study shows that patients with a family history are being screened and diagnosed with prostate cancer earlier. Careful screening may have contributed to the good results we observed."

Study co-authors include Hilary Bagshaw, Karen Ruth, Eric M. Horwitz, and David Chen from.

Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).

Diana Quattrone | EurekAlert!
Further information:
http://www.fccc.edu

Further reports about: Nobel Prize PSA family history prostate cancer risk factor

More articles from Health and Medicine:

nachricht Correct connections are crucial
26.06.2017 | Charité - Universitätsmedizin Berlin

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Touch Displays WAY-AX and WAY-DX by WayCon

27.06.2017 | Power and Electrical Engineering

Drones that drive

27.06.2017 | Information Technology

Ultra-compact phase modulators based on graphene plasmons

27.06.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>